"Biopharmaceutical company Innate Pharma SA (euronext paris:FR0010331421) reported on Monday that it has started the cohort expansion portion of the Phase I clinical trial testing the combination of the two investigational checkpoint inhibitors lirilumab and nivolumab in selected solid tumors...


"The company said the trial will test lirilumab (anti-KIR checkpoint inhibitor; BMS-986015) in combination with nivolumab (anti-PD-1 checkpoint inhibitor BMS-936558) in solid tumors. The Phase I open label study will evaluate the safety of the combination of lirilumab and nivolumab and to provide preliminary information on the clinical activity of the combination. The primary outcome is safety."


Editor's note: Nivolumab is an immunotherapy drug that activates the immune system's T cells in the hopes that the patient's own immune system will be prompted to fight tumors. Nivolumab has already been shown to be a promising melanoma treatment on its own. Lirilumab is a drug that activates a different group of immune system cells known as natural killer cells (NK). This clinical trial combines both drugs to see if they work better together.